This book summarizes the current status and future trends in the development of radiopharmaceuticals for sentinel lymph node detection (SLND), an essential diagnostic tool for the effective treatment of superficial cancers such as breast tumours and melanoma. The publication covers all current aspects of this diagnostic methodology, including the production of nanocolloidal particles, their biological mechanism of action and relevant clinical applications. It also illustrates the recent developments in the field fuelled by the introduction of molecular imaging agents for SLND and of multimodality optical and radioactive agents. Included in the results presented in this book, are those on the novel generation of SLND radiopharmaceuticals obtained through an IAEA coordinated research project.